Ginkgo Bioworks Holdings Inc.(DNA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

DNA Ginkgo Bioworks Holdings Inc.

Not Yet Opened 11-25 16:00:00 EST

8.14

+0.96

+13.37%

盘后8.19

+0.05+0.58%

19:58 EST

High8.14	Low7.36	Vol1.33M
Open7.41	D1 Closing7.18	Amplitude10.93%
Mkt Cap467.88M	Tradable Cap325.75M	Total Shares57.48M
T/O10.43M	T/O Rate3.31%	Tradable Shares40.02M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"DNA","market":"US","secType":"STK","nameCN":"Ginkgo Bioworks Holdings Inc.","latestPrice":8.14,"timestamp":1732568400000,"preClose":7.18,"halted":0,"volume":1325806,"hourTrading":{"tag":"盘后","latestPrice":8.1869,"preClose":8.14,"latestTime":"19:58 EST","volume":19688,"amount":160007.4657,"timestamp":1732582701378},"delay":0,"floatShares":40018900,"shares":57478905,"eps":-12.861042,"marketStatus":"Not Yet Opened","change":0.96,"latestTime":"11-25 16:00:00 EST","open":7.41,"high":8.14,"low":7.355,"amount":10430959.014616,"amplitude":0.109331,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-12.861042,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1732611600000},"marketStatusCode":0,"adr":0,"exchange":"NYSE","adjPreClose":7.18,"preHourTrading":{"tag":"盘前","latestPrice":7.33,"preClose":7.18,"latestTime":"09:28 EST","volume":4034,"amount":29600.3487644,"timestamp":1732544927252},"postHourTrading":{"tag":"盘后","latestPrice":8.1869,"preClose":8.14,"latestTime":"19:58 EST","volume":19688,"amount":160007.4657,"timestamp":1732582701378},"volumeRatio":1.092512,"impliedVol":1.0177,"impliedVolPercentile":0.6932},"requestUrl":"/m/hq/s/DNA/wiki","defaultTab":"wiki","newsList":[{"id":"2486484062","title":"Exact Sciences Advances Breast Cancer Care with the Oncotype DX® test and Genomic Profiling Research at SABCS 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2486484062","media":"Business Wire","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486484062?lang=en_us&edition=fundamental","pubTime":"2024-11-26 06:35","pubTimestamp":1732574100,"startTime":"0","endTime":"0","summary":"New data supports the value of the Oncotype DX Breast Recurrence Score test in guiding treatment decisions, improving outcomes, and managing costs for breast cancer patients globally. \"Exact Sciences is committed to improving breast cancer care by providing actionable insights that support informed treatment decisions and help achieve the best outcomes for patients across all backgrounds,\" said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology at Exact Sciences. \"For 20 years, the Oncotype DX test has led the way in personalized treatment planning, and the new findings presented at SABCS reinforce its trusted role among clinicians, research institutions, and patients alike. With the addition of our OncoExTra test and our anticipated molecular residual disease monitoring test, we’re equipping clinicians with innovative solutions to support patient needs throughout every stage of cancer care.\". Title: The Oncotype DX test to guide adjuvant chemotherapy treatment decisions for e","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/WeIMnnbKF_H70QDPZuJv6A--~B/aD0yNDE7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/861aa8c4ebc61887b151ac6fb8b7a642","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/WeIMnnbKF_H70QDPZuJv6A--~B/aD0yNDE7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/861aa8c4ebc61887b151ac6fb8b7a642"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exact-sciences-advances-breast-cancer-223500966.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["DNA","BK4139","LU1861558580.USD","BK4585","BK4505","RNA","BK4548","BK4110","BK4588","BK4109","DX","EXAS","LU0266013472.USD","LU1861559042.SGD"],"gpt_icon":0},{"id":"2486957087","title":"CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2486957087","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486957087?lang=en_us&edition=fundamental","pubTime":"2024-11-25 22:00","pubTimestamp":1732543200,"startTime":"0","endTime":"0","summary":"Poster presented at the 29th Annual Meeting of the Society for Neuro-Oncology . Primary analysis data in potentially pivotal GBM study with lead program, Berubicin, on track for the first half of 2025. All grades of any reported adverse events and those of Grade 3-5 in severity occurring in more than 10% of patients are shown to be relatively similar in the Berubicin and Lomustine arms. A slightly greater percentage of patients with all grades or Grades 3-5 with anaemia, headache, and decrease in neutrophil counts were shown in patients receiving Berubicin, while","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Qxw8V8jPKeVzH7_nzi2c.w--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/bdd404f4d491dff4236c8f8dba67064c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Qxw8V8jPKeVzH7_nzi2c.w--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/bdd404f4d491dff4236c8f8dba67064c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cns-pharmaceuticals-presents-ongoing-potentially-140000579.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4007","BK4109","DNA","BK4097","BK4124","CNSP","SMP","OS","CNS","BK4135"],"gpt_icon":0},{"id":"2484152551","title":"Lucid Diagnostics submits clinical evidence for EsoGuard Esophagea DNA test","url":"https://stock-news.laohu8.com/highlight/detail?id=2484152551","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484152551?lang=en_us&edition=fundamental","pubTime":"2024-11-20 21:00","pubTimestamp":1732107621,"startTime":"0","endTime":"0","summary":"Lucid Diagnostics (LUCD), a subsidiary of PAVmed (PAVM), announced that it has submitted its complete clinical evidence package for its EsoGuard Es...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lucid-diagnostics-submits-clinical-evidence-for-esoguard-esophagea-dna-test?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lucid-diagnostics-submits-clinical-evidence-for-esoguard-esophagea-dna-test?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PAVM","BK4109","BK4099","DNA","BK4551","BK4082","BK4596","BK4555","BK4139","LUCD"],"gpt_icon":0},{"id":"2484115668","title":"Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test","url":"https://stock-news.laohu8.com/highlight/detail?id=2484115668","media":"PR Newswire","labels":["Policy And Regulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484115668?lang=en_us&edition=fundamental","pubTime":"2024-11-20 20:56","pubTimestamp":1732107360,"startTime":"0","endTime":"0","summary":"\"This submission is the culmination of many years of persistent hard work by our team and our many clinical research partners, and represents perhaps the most important milestone in Lucid's history,\" said Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer. \"We believe the data in this package strongly supports EsoGuard's clinical validity, utility, and analytical accuracy, aligning with the MolDX criteria for coverage as outlined in the LCD. The clinical validity data, in particular, demonstrates EsoGuard's unprecedented precancer detection performance across all studies. We look forward to the opportunity to expand access to EsoGuard precancer testing to all at-risk Medicare beneficiaries.\". The EsoGuard clinical evidence package includes six new peer-reviewed publications: three clinical validation studies , two clinical utility studies, and one analytical validation study. The current LCD provides clear coverage criteria consistent with the American College of Gastroen","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/cNb4vYrfvYmKz8.h.dXgbA--~B/aD0xMDc7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/9ee0d0ae0eda5368bcc0b17e848d707c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/cNb4vYrfvYmKz8.h.dXgbA--~B/aD0xMDc7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/9ee0d0ae0eda5368bcc0b17e848d707c"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/lucid-diagnostics-submits-clinical-evidence-125600161.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lucid-diagnostics-submits-clinical-evidence-125600161.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4551","BK4596","BK4099","BK4208","BK4080","BK4231","LU1894683264.USD","BK4109","LU1894683348.USD","LU2346227817.USD","BK4588","LU2637428348.USD","MAC","CMS","DNA","LUCD","BK4555","BK4585","PAVM","PAVMZ","BK4082","BK4139"],"gpt_icon":1},{"id":"2484666912","title":"Applied DNA Sciences files to sell 41.64M shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2484666912","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484666912?lang=en_us&edition=fundamental","pubTime":"2024-11-19 19:26","pubTimestamp":1732015571,"startTime":"0","endTime":"0","summary":"06:20 EST Applied DNA Sciences (APDN) files to sell 41.64M shares of common stock for holders Published first on TheFly – the ultimate source for r...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/applied-dna-sciences-files-to-sell-41-64m-shares-of-common-stock-for-holders?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/applied-dna-sciences-files-to-sell-41-64m-shares-of-common-stock-for-holders?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DNA","BK4139","BK4121","APDN","BK4109","BK4583"],"gpt_icon":0},{"id":"2483320450","title":"Ginkgo Bioworks price target lowered to $6 from $7 at BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2483320450","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483320450?lang=en_us&edition=fundamental","pubTime":"2024-11-15 20:30","pubTimestamp":1731673815,"startTime":"0","endTime":"0","summary":"BTIG analyst Mark Massaro lowered the firm’s price target on Ginkgo Bioworks (DNA) to $6 from $7 and keeps a Sell rating on the shares after its Q3...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ginkgo-bioworks-price-target-lowered-to-6-from-7-at-btig?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ginkgo-bioworks-price-target-lowered-to-6-from-7-at-btig?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DNA","BK4139","BK4109"],"gpt_icon":0},{"id":"2483932076","title":"Ginkgo Bioworks Holdings Third Quarter 2024 Earnings: Beats Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2483932076","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483932076?lang=en_us&edition=fundamental","pubTime":"2024-11-15 19:37","pubTimestamp":1731670647,"startTime":"0","endTime":"0","summary":"NYSE:DNA Earnings and Revenue Growth November 15th 2024. All figures shown in the chart above are for the trailing 12 month  period. Revenue exceeded analyst estimates by 98%. Earnings per share  also surpassed analyst estimates by 67%.Looking ahead, revenue is forecast to grow 4.2% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Chemicals industry in the US.The company's shares are down 13% from a week ago.Be aware that  Ginkgo Bioworks Holdings is showing  3 warning signs in our investment analysis that you should know about...","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ginkgo-bioworks-holdings-third-quarter-113727321.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["DNA"],"gpt_icon":0},{"id":"2483886201","title":"Ginkgo Bioworks Holdings Inc reports results for the quarter  - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2483886201","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483886201?lang=en_us&edition=fundamental","pubTime":"2024-11-13 22:20","pubTimestamp":1731507646,"startTime":"0","endTime":"0","summary":"* Ginkgo Bioworks Holdings Inc    reported a quarterly adjusted loss of 94 cents per share for the quarter , higher than the same quarter last year, when the company reported EPS of $-6.40.  The mean ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Ginkgo Bioworks Holdings Inc reports results for the quarter  - Earnings Summary","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DNA"],"gpt_icon":0},{"id":"2483078520","title":"Myriad Genetics Expands Access to At-Home Early Fetal Sex DNA Test with Retail Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2483078520","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483078520?lang=en_us&edition=fundamental","pubTime":"2024-11-13 21:00","pubTimestamp":1731502800,"startTime":"0","endTime":"0","summary":"SneakPeek, the first at-home early fetal sex test for use at six weeks, is now available at over 8,800 retail locations nationwide. SALT LAKE CITY, Nov. 13, 2024  -- Myriad Genetics, Inc., , a leader in genetic testing and precision medicine, continues to empower parents with increased access to prenatal testing. SneakPeek, the #1 OBGYN-recommended gender test with over 99% accuracy,[1] is now available over the counter in more than 8,800 retail locations nationwide. The product is the first of its kind to be sold on shelf in Walmart stores greatly expanding access for expectant parents who want to learn if they’re having a girl or boy at-home as early as six weeks into pregnancy.How the Test WorksThe retail test kit includes the patented SneakPeek Snap device, which is placed on the user’s upper arm to nearly painlessly collect a blood sample with the simple press of a button. The sample is then mailed to the SneakPeek laboratory in the included, postage-paid envelope. Test results ar","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/PxSpopFzvNo6kLYaTtdcqA--~B/aD0yMTM7dz00NjQ7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/45c79e87fecfe1a776ab5a2d786a4f30","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/PxSpopFzvNo6kLYaTtdcqA--~B/aD0yMTM7dz00NjQ7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/45c79e87fecfe1a776ab5a2d786a4f30"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/myriad-genetics-expands-access-home-130000657.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4211","BK4109","DNA","MYGN","BK4139","HBCP","BK4195"],"gpt_icon":1},{"id":"2483773067","title":"Ginkgo Bioworks surges 14% as it ups 2024 revenue forecast","url":"https://stock-news.laohu8.com/highlight/detail?id=2483773067","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483773067?lang=en_us&edition=fundamental","pubTime":"2024-11-13 06:33","pubTimestamp":1731450803,"startTime":"0","endTime":"0","summary":"filo Ginkgo Bioworks  has soared ~14% higher in post-market trading Tuesday after posting Q3 results that beat on both lines and raising its 2024 revenue outlook range. The cell programming platform company now sees full-year revenue of $215M-235M, up from $170M-$190M prior. Consensus is $185.52M.","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1975508657/image_1975508657.jpg?io=getty-c-w750","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1975508657/image_1975508657.jpg?io=getty-c-w750"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4282502-ginkgo-bioworks-surges-14-as-it-ups-2024-revenue-forecast","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["DNA"],"gpt_icon":0},{"id":"2483066910","title":"Ginkgo Bioworks Holdings GAAP EPS of -$1.08 beats by $2.24, revenue of $89.05M beats by $44.06M","url":"https://stock-news.laohu8.com/highlight/detail?id=2483066910","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483066910?lang=en_us&edition=fundamental","pubTime":"2024-11-13 06:10","pubTimestamp":1731449417,"startTime":"0","endTime":"0","summary":"Ginkgo Bioworks Holdings press release : Q3 GAAP EPS of -$1.08  beats by $2.24. Revenue of $89.05M   beats by $44.06M.  Q4 Outlook: Ginkgo previously issued 2024 guidance for Total revenue of $170-190 million; Cell Engineering services revenue of $120-140 million; and Biosecurity","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4282492-ginkgo-bioworks-holdings-gaap-eps-of-1_08-beats-2_24-revenue-of-89_05m-beats-44_06m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["DNA"],"gpt_icon":0},{"id":"2483406309","title":"Ginkgo Bioworks Holdings Q3 EPS $(1.08) Beats $(2.71) Estimate, Sales $89.05M Beat $45.00M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2483406309","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483406309?lang=en_us&edition=fundamental","pubTime":"2024-11-13 06:04","pubTimestamp":1731449055,"startTime":"0","endTime":"0","summary":"Ginkgo Bioworks Holdings (NYSE:DNA) reported quarterly losses of $(1.08) per share which beat the analyst consensus estimate of $(2.71) by 60.15 percent. This is a 82.61 percent increase over losses of $(6.21) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41922742/ginkgo-bioworks-holdings-q3-eps-1-08-beats-2-71-estimate-sales-89-05m-beat-45-00m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Ginkgo Bioworks Holdings Q3 EPS $(1.08) Beats $(2.71) Estimate, Sales $89.05M Beat $45.00M Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DNA"],"gpt_icon":0},{"id":"2483606303","title":"Ginkgo Bioworks Holdings Inc: Reduction in Force Is Estimated to Achieve Over $85 Mln in Annualized Savings by Mid-2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2483606303","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483606303?lang=en_us&edition=fundamental","pubTime":"2024-11-13 06:01","pubTimestamp":1731448865,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241112:nTUABRKP1H:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4109","DNA","BK4139"],"gpt_icon":0},{"id":"2483063031","title":"Ginkgo Bioworks: Will Substantially Consolidate Overall Real Estate Footprint by Exiting Several Facilities in Cambridge, Ma and Europe by Yr End","url":"https://stock-news.laohu8.com/highlight/detail?id=2483063031","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483063031?lang=en_us&edition=fundamental","pubTime":"2024-11-13 06:01","pubTimestamp":1731448865,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241112:nTUABRKP1H:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4109","DNA","BK4139"],"gpt_icon":0},{"id":"2483065324","title":"Press Release: Ginkgo Bioworks Reports Third Quarter 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2483065324","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483065324?lang=en_us&edition=fundamental","pubTime":"2024-11-13 06:01","pubTimestamp":1731448860,"startTime":"0","endTime":"0","summary":"Ginkgo provides update on its restructuring process including an acceleration of site consolidation initiatives and continued progress on cost reductions. Ginkgo signs new and expanded deals with Novo Nordisk and achieves a major research milestone with Merck. -- Third quarter 2024 Total revenue of $89 million, up from $55 million in. the comparable prior year period, an increase of 61% driven by $45. million of non-cash revenue from a release of deferred revenue relating. to the mutual termination of a customer agreement. Excluding this impact,Total revenue in the quarter was $44 million, a decrease of 21% over the. -- Excluding the $45 million non-cash deferred revenue release, third. quarter 2024 Cell Engineering revenue of $30 million, down from. driven by the continued shift from early stage customers to. -- Third quarter 2024 Biosecurity revenue of $14 million with gross. profit margin of 28%. Biosecurity revenue decreased from the. impairments, of $124 million) in the comparable","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRO","BK4139","DNA","BK4109"],"gpt_icon":0},{"id":"2482108109","title":"Ginkgo Bioworks Advances Collaboration with Merck","url":"https://stock-news.laohu8.com/highlight/detail?id=2482108109","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482108109?lang=en_us&edition=fundamental","pubTime":"2024-11-12 23:19","pubTimestamp":1731424788,"startTime":"0","endTime":"0","summary":"Ginkgo Bioworks Holdings  said Tuesday that it will receive a research milestone payment of $9 million from Merck  after completing the first milestone in their partnership.They will now advance to the next phase, which will focus on continuing to improve the production process, Ginkgo Bioworks said.Price: 8.68, Change: -0.08, Percent Change: -0.91","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1061106388.HKD","LU0208291251.USD","LU1934455194.USD","LU0203347892.USD","MRK","BK4516","LU0006306889.USD","IE0009355771.USD","LU0965508806.USD","IE00B1BXHZ80.USD","BK7078","LU0122379950.USD","IE00BBT3K403.USD","LU0058720904.USD","LU0234572021.USD","IE00BLSP4452.SGD","LU1066051811.HKD","LU1116320901.HKD","LU1291159041.SGD","LU1037948897.HKD","IE00BLSP4239.USD","DNA","LU0320765489.SGD","LU1037948541.HKD","LU0861579265.USD","IE00B2B36J28.USD","IE00BN8TJ469.HKD","LU1934455863.HKD","BK4585","BK4559","BK4533","LU0289739699.SGD","LU1917777945.USD","IE00BSNM7G36.USD","LU0266013472.USD","IE00BJJMRZ35.SGD","LU0238689110.USD","DNA.AU","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","BK4588","IE0002141913.USD","BK4550","LU1934455277.USD","LU1066051225.USD","IE000M9KFDE8.USD","LU1066051498.USD","LU0070302665.USD","LU1057294990.SGD","LU1093756168.USD"],"gpt_icon":0},{"id":"2482660083","title":"Ginkgo Bioworks completes first milestone in Merck collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2482660083","media":"seekingalpha","labels":["Policy And Regulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482660083?lang=en_us&edition=fundamental","pubTime":"2024-11-12 22:25","pubTimestamp":1731421552,"startTime":"0","endTime":"0","summary":"Eoneren/E+ via Getty Images  Ginkgo Bioworks  announced the completion of the first milestone of a previously announced partnership with Merck, focused on improving biologic manufacturing. As part of this milestone completion, Ginkgo will receive a research milestone payment of $9M in cash. The","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1346213103/image_1346213103.jpg?io=getty-c-w750","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1346213103/image_1346213103.jpg?io=getty-c-w750"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4280085-ginkgo-bioworks-completes-first-milestone-in-merck-collaboration","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["LU0203347892.USD","IE00BN8TJ469.HKD","LU1023059063.AUD","LU0965509010.AUD","LU0211331839.USD","LU0238689110.USD","IE00BJT1NW94.SGD","IE00B1BXHZ80.USD","IE00BSNM7G36.USD","LU1430594728.SGD","LU0965509283.SGD","BK4550","DNA","LU1037948541.HKD","LU0006306889.USD","LU1066051811.HKD","BK4139","LU0070302665.USD","LU1061106388.HKD","LU0106261372.USD","LU1934455863.HKD","LU0965508806.USD","IE00B2B36J28.USD","LU1057294990.SGD","LU1917777945.USD","LU1116320737.USD","IE0009355771.USD","LU1934455194.USD","IE00BFTCPJ56.SGD","IE0002141913.USD","MRK","LU1093756168.USD","IE000M9KFDE8.USD","LU0985320562.USD","LU1066051225.USD","BK4533","LU0265550359.USD","LU0861579265.USD","BK4588","BK4585","LU0058720904.USD","LU0122379950.USD","LU1093756325.SGD","BK4109","LU1291159041.SGD","IE00BLSP4452.SGD","IE00BLSP4239.USD","LU0965509101.SGD","BK4559","LU0234572021.USD"],"gpt_icon":0},{"id":"2482227709","title":"BRIEF-Ginkgo Bioworks Advances Collaboration With Merck To Improve Biologics Manufacturing","url":"https://stock-news.laohu8.com/highlight/detail?id=2482227709","media":"Reuters","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482227709?lang=en_us&edition=fundamental","pubTime":"2024-11-12 21:03","pubTimestamp":1731416628,"startTime":"0","endTime":"0","summary":"Nov 12  - Ginkgo Bioworks Holdings Inc   :   * GINKGO BIOWORKS ADVANCES COLLABORATION WITH MERCK TO IMPROVE BIOLOGICS MANUFACTURING   * GINKGO BIOWORKS HOLDINGS INC - TO RECEIVE $9 MILLION RESEARCH MILESTONE PAYMENTSource text:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B4R5TH58.HKD","LU0266013472.USD","LU0965508806.USD","LU1093756325.SGD","LU1291159041.SGD","LU0965509010.AUD","BK4516","BK4559","IE00BSNM7G36.USD","MRK","LU1037948897.HKD","LU1066053197.SGD","LU0208291251.USD","LU1066051498.USD","IE0009355771.USD","LU0106261372.USD","LU0203345920.USD","LU0965509101.SGD","LU1061106388.HKD","IE0002141913.USD","LU0122379950.USD","IE00BFTCPJ56.SGD","LU0058720904.USD","LU0203347892.USD","BK4533","LU1116320901.HKD","BK4550","IE00BJJMRZ35.SGD","BK4585","LU0211331839.USD","DNA","IE000M9KFDE8.USD","IE00B2B36J28.USD","LU0289739699.SGD","LU1430594728.SGD","IE00B1BXHZ80.USD","LU1057294990.SGD","LU1066051225.USD","LU1934455277.USD","LU1941712264.USD","LU1585245621.USD","LU1037948541.HKD","LU1934455194.USD","LU1116320737.USD","LU0965509283.SGD","IE00BLSP4452.SGD","LU0265550946.USD","IE00BJT1NW94.SGD","BK4007","BK4109"],"gpt_icon":0},{"id":"2482078425","title":"Tempus Publishes Study Highlighting Benefits of Concurrent RNA and DNA Sequencing in Advanced Cancer Care","url":"https://stock-news.laohu8.com/highlight/detail?id=2482078425","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482078425?lang=en_us&edition=fundamental","pubTime":"2024-11-11 21:30","pubTimestamp":1731331800,"startTime":"0","endTime":"0","summary":"CHICAGO, November 11, 2024----Tempus AI, Inc. , a technology company leading the adoption of AI to advance precision medicine and patient care, today announced publication of its study, \"Actionable structural variant detection via RNA-NGS and DNA-NGS in patients with advanced non-small cell lung cancer,\" in JAMA Network Open.\"This large study underscores the importance of using both RNA- and DNA-based comprehensive genomic profiling as a standard of care in advanced NSCLC, and more broadly in solid tumors,\" said Halla Nimeiri, MD, Chief Development Officer at Tempus. \"By integrating RNA and DNA sequencing, we can detect a wider range of actionable alterations that might otherwise go undetected by DNA testing alone. This combined approach enhances clinicians' ability to provide more personalized treatment options for patients.\"","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/xFb4bpUMLbv.i5Lu1OtM_w--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/cc017a623bfa90c00b474f5692bf3306","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/xFb4bpUMLbv.i5Lu1OtM_w--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/cc017a623bfa90c00b474f5692bf3306"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tempus-publishes-study-highlighting-benefits-133000970.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NGS","RNA","BK4109","AEIS","IE0031619046.USD","IE00B7SZL793.SGD","BK4139","WRD","TEM","BK4505","IE00B66KJ199.SGD","BK4157","BK4121","BK4585","IE00B19Z4B17.USD","BK4179","BK4588","DNA"],"gpt_icon":0},{"id":"2482293084","title":"We Think Installed Building Products (NYSE:IBP) Might Have The DNA Of A Multi-Bagger","url":"https://stock-news.laohu8.com/highlight/detail?id=2482293084","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482293084?lang=en_us&edition=fundamental","pubTime":"2024-11-10 21:48","pubTimestamp":1731246538,"startTime":"0","endTime":"0","summary":"What are the early trends we should look for to identify a stock that could multiply in value over the long term...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/4113000-choice2-main-header/1585186663126","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/4113000-choice2-main-header/1585186663126"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/consumer-durables/nyse-ibp/installed-building-products/news/we-think-installed-building-products-nyseibp-might-have-the-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4109","IE00B2PGVK34.USD","BK4139","IBP","EBIT","DNA","IE00B3CCJ633.GBP","IE00BGHQF417.EUR","NYSE","BK4088"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ginkgobioworks.com","stockEarnings":[{"period":"1week","weight":0.2859},{"period":"1month","weight":-0.0025},{"period":"3month","weight":0.081},{"period":"6month","weight":-0.6371},{"period":"1year","weight":-0.8606},{"period":"ytd","weight":-0.8796}],"compareEarnings":[{"period":"1week","weight":0.0159},{"period":"1month","weight":0.0319},{"period":"3month","weight":0.0641},{"period":"6month","weight":0.1358},{"period":"1year","weight":0.3124},{"period":"ytd","weight":0.2571}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.136854},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.079149},{"month":3,"riseRate":0,"avgChangeRate":-0.145508},{"month":4,"riseRate":0,"avgChangeRate":-0.198305},{"month":5,"riseRate":0.5,"avgChangeRate":-0.021474},{"month":6,"riseRate":0.5,"avgChangeRate":-0.102098},{"month":7,"riseRate":0.75,"avgChangeRate":0.169703},{"month":8,"riseRate":0.25,"avgChangeRate":-0.169227},{"month":9,"riseRate":0.75,"avgChangeRate":0.07852},{"month":10,"riseRate":0.25,"avgChangeRate":-0.06018},{"month":11,"riseRate":0.25,"avgChangeRate":-0.100579},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.046864}],"exchange":"NYSE","name":"Ginkgo Bioworks Holdings Inc.","nameEN":"Ginkgo Bioworks Holdings Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Ginkgo Bioworks Holdings Inc.(DNA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Ginkgo Bioworks Holdings Inc.(DNA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Ginkgo Bioworks Holdings Inc.,DNA,Ginkgo Bioworks Holdings Inc.股票,Ginkgo Bioworks Holdings Inc.股票老虎,Ginkgo Bioworks Holdings Inc.股票老虎国际,Ginkgo Bioworks Holdings Inc.行情,Ginkgo Bioworks Holdings Inc.股票行情,Ginkgo Bioworks Holdings Inc.股价,Ginkgo Bioworks Holdings Inc.股市,Ginkgo Bioworks Holdings Inc.股票价格,Ginkgo Bioworks Holdings Inc.股票交易,Ginkgo Bioworks Holdings Inc.股票购买,Ginkgo Bioworks Holdings Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Ginkgo Bioworks Holdings Inc.(DNA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Ginkgo Bioworks Holdings Inc.(DNA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction